ecteinascidin 743 has been researched along with Osteogenic Sarcoma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, K; Horiuchi, K; Inoue, M; Ishizaka, T; Matsuhashi, Y; Rikitake, H; Susa, M; Taguchi, E | 1 |
| Bongiovanni, L; Botti, L; Burocchi, A; Cancila, V; Cappetti, B; Chiodoni, C; Colombo, MP; Galvan, S; Garofalo, C; Manara, MC; Parenza, M; Ratti, C; Sangaletti, S; Scotlandi, K; Torselli, I; Tripodo, C; Valenti, CF | 1 |
| Aglietta, M; Aliberti, S; Bardelli, A; Bartolini, A; Bertulli, R; Boccone, P; Chiabotto, G; D'Ambrosio, L; D'Incalci, M; Dei Tos, AP; Ferrari, S; Grignani, G; Marchesi, E; Miano, S; Novara, L; Palmerini, E; Piana, R; Picci, P; Pignochino, Y; Pisacane, A; Sangiolo, D; Stacchiotti, S; Tolomeo, F; Zucchetti, M | 1 |
| Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Constantinidou, A; Jones, RL; Loggers, E; Pollack, S; Rodler, E | 1 |
| Gastaud, L; Ianessi, A; Italiano, A; Le Morvan, V; Pourquier, P; Saâda-Bouzid, E; Thariat, J; Thyss, A | 1 |
| Budd, GT; Wesolowski, R | 1 |
| Benini, S; Cerisano, V; D'Incalci, M; Faircloth, G; Manara, MC; Mercuri, M; Perdichizzi, S; Picci, P; Reverter-Branchat, G; Scotlandi, K; Serra, M; Strammiello, R | 1 |
| Bagatell, R; Demetri, GD; Goorin, AM; Gorlick, R; Guzman, C; Harmon, D; Healey, JH; Huvos, AG; Jimeno, J; Kolb, EA; Laverdiere, C; Maki, RG; Meyers, PA; Ruiz-Casado, A; Supko, JG; Wexler, L | 1 |
3 review(s) available for ecteinascidin 743 and Osteogenic Sarcoma
| Article | Year |
|---|---|
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin | 2019 |
The evolution of systemic therapy in sarcoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chordoma; Deoxycytidine; Dermatofibrosarcoma; Dioxoles; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Hemangiosarcoma; Humans; Osteosarcoma; Proteasome Inhibitors; Receptor, IGF Type 1; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2013 |
Use of chemotherapy for patients with bone and soft-tissue sarcomas.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Dioxoles; Humans; Muscle Neoplasms; Osteosarcoma; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2010 |
2 trial(s) available for ecteinascidin 743 and Osteogenic Sarcoma
| Article | Year |
|---|---|
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Italy; Male; Middle Aged; Osteosarcoma; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Sarcoma; Soft Tissue Neoplasms; Time Factors; Trabectedin | 2018 |
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Dioxoles; Female; Humans; Isoquinolines; Male; Middle Aged; Osteosarcoma; Salvage Therapy; Tetrahydroisoquinolines; Trabectedin | 2003 |
5 other study(ies) available for ecteinascidin 743 and Osteogenic Sarcoma
| Article | Year |
|---|---|
Trabectedin suppresses osteosarcoma pulmonary metastasis in a mouse tumor xenograft model.
Topics: Adolescent; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Heterografts; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Osteosarcoma; Trabectedin | 2022 |
Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Topics: Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cellular Reprogramming; Core Binding Factor Alpha 1 Subunit; Dioxoles; Humans; Immunotherapy; Lung Neoplasms; Osteosarcoma; Programmed Cell Death 1 Receptor; T-Lymphocytes; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2017 |
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Topics: Adolescent; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Irinotecan; Male; Mice, Nude; Osteosarcoma; Topoisomerase I Inhibitors; Trabectedin | 2019 |
Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.
Topics: Adolescent; Biomarkers, Tumor; Bone Neoplasms; Dioxoles; DNA-Binding Proteins; Endonucleases; Female; Genetic Markers; Humans; Male; Nuclear Proteins; Osteosarcoma; Polymorphism, Single Nucleotide; Tetrahydroisoquinolines; Trabectedin; Transcription Factors; Treatment Outcome; Young Adult | 2013 |
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Cell Differentiation; Dioxoles; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Isoquinolines; Nuclear Proteins; Osteosarcoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Retinoblastoma Protein; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |